About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72722 record(s)
Req # A-2022-000459
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108879-949.Organization: Health Canada
September 2024
Req # A-2023-000723
Adverse Drug Reactions (ADRs). Report numbers: E2B_05649767, E2B_02763747, 000972665, E2B_05628398, E2B_06216442, E2B_06186458, E2B_03293332, E2B_06030016, 001034630, E2B_06264505.Organization: Health Canada
September 2024
Req # A-2023-001039
Adverse Drug Reaction (ADR). Report number: E2B_06496077.Organization: Health Canada
September 2024
Req # A-2023-001309
Adverse Drug Reactions (ADRs). Report numbers: E2B_06451765, 1043220, E2B_06450183, 1050539, 1050563, 1052286, E2B_06566392, 1052822.Organization: Health Canada
September 2024
Req # A-2023-001333
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_06719295, E2B_06758044. ADR for Pantoloc. Report number: 001066050. ADRs for Pantoprazole sodium. Report numbers: E2B_06731244, E2B_06741613. ADRs for Tecta. Report numbers:…Organization: Health Canada
September 2024
Req # A-2023-001497
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_06824978, E2B_06818170, E2B_06781412, E2B_06818361, E2B_06766936, E2B_06810905, E2B_06813780, E2B_06809546, E2B_06829661, E2B_06818363.Organization: Health Canada
September 2024
Req # A-2023-001533
Adverse Drug Reactions (ADRs). Report numbers: E2B_06779032, E2B_06779961, E2B_06779926, 001072788, E2B_06806126, E2B_06410273, 001068894, 001067286, E2B_06822633.Organization: Health Canada
September 2024
Req # A-2024-000128
Adverse Drug Reactions (ADRs) for Morphine. Report numbers: 001075170, E2B_06906193. ADRs for Hydromorphone. Report numbers: 001075282, 001075286, 001075300, 001075304, 001075301, 001075303, 001075648. ADRs for Heparin. Report numbers: 001076801,…Organization: Health Canada
September 2024
Req # A-2024-000146
Adverse Drug Reactions (ADRs). Report numbers: E2B_07024147, 001086222, 001079010, 001078146, 001078143.Organization: Health Canada
September 2024
Req # A-2024-000175
Adverse Drug Reaction (ADR). Report number: E2B_06517909.Organization: Health Canada
September 2024